# US 2021/0340627 A1 · Dna methylation-related marker for diagnosing tumor, and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340627 A1
- Document ID: US20210340627A1
- Status: Published application
- Kind: A1
- Application number: 17/268,268
- Filed: 2019-08-08
- Published: 2021-11-04
- Earliest claimed: 2018-08-16
- Assignees: Shanghai Public Health Clinical Center
- Applicants: Shanghai Public Health Clinical Center
- Inventors: Wenqiang YU; Shihua DONG
- Web page: https://patentgrep.com/patent/US20210340627A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided are DNA methylation related markers for diagnosis of tumors and application thereof. Disclosed are gene sequence regions having abnormal DNA methylation in the genome, named tumor markers CTSM-4F, CTSM-2BE, CTSM-3C, CTSM-4I. The methylation levels of those sequence regions are significantly different between tumor tissues and non-tumor tissues, with their CpG(s) hypermethylated in tumor tissues.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

An isolated polynucleotide, wherein, the polynucleotide is converted from the polynucleotide of SEQ ID NO: 1, 3, 5 or 7 or the fragments thereof, and as compared with the sequence of SEQ ID NO: 1, 3, 5 or 7, its cytosine C of the CpG site(s) with modification is unchanged, and the unmodified cytosine is converted into T.

### Claim 15 (depends on 14)

The polynucleotide according to claim 14, wherein the polynucleotide comprises:
(g) the polynucleotide with the nucleotide sequence shown in SEQ ID NO: 2;
(h) the polynucleotide with the nucleotide sequence shown in SEQ ID NO: 4;
(i) the polynucleotide with the nucleotide sequence shown in SEQ ID NO: 6;
(j) the polynucleotide with the nucleotide sequence shown in SEQ ID NO: 8;
(k) a fragment of the polynucleotide of (g)-(j), having at least one CpG site with modification.

### Claim 16

A method for detecting tumor, comprises detecting the DNA methylation status of the polynucleotide with the nucleotide sequence shown in SEQ ID NO: 1, 2, 5 or 7 or the fragments thereof, if the CpG sites are significantly hypermethylated, the subject is high-risk for tumor.

### Claim 17 (depends on 16)

The method according to claim 16, wherein, the tumors comprise: digestive system tumors such as esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, bile duct and gallbladder cancer; respiratory system tumors such as lung cancer, pleuroma; hematologic cancers such as leukemia, lymphoma, multiple myeloma; gynecological and reproductive system tumors such as breast cancer, ovarian cancer, cervical cancer, vulvar cancer, testicular cancer, prostate cancer, penile cancer; nervous system tumors such as glioma, neuroblastoma, meningioma; head and neck tumors such as oral cancer, tongue cancer, laryngeal cancer, nasopharyngeal cancer; urinary system tumors such as kidney cancer, bladder cancer, skin and other systems tumors such as skin cancer, melanoma, osteosarcoma, liposarcoma, thyroid cancer.

### Claim 18 (depends on 16)

The method according to claim 16, wherein, use agent or a combination of agents to detect the DNA methylation status of the polynucleotide with the nucleotide sequence shown in SEQ ID NO: 1, 2, 5 or 7 or the fragments thereof, the agent is a primer or a probe.

### Claim 19 (depends on 18)

The method according claim 18, wherein, the primers are as shown in SEQ ID NO: 9-12, or SEQ ID NO: 12-15, or SEQ ID NO: 12 and 16-18, or SEQ ID NO: 12 and 19-21.

### Claim 20 (depends on 14)

A method of preparing a tumor detection agent, comprising: providing the polynucleotide of SEQ ID NO: 1, 3, 5, 7 or the fragments thereof, or the polynucleotide of claim 14, designing a detection agent for specifically detecting a target sequence which is the full length or fragment of the polynucleotide; wherein, the target sequence has at least one modified CpG site.

### Claim 21 (depends on 20)

The method of claim 20, wherein the detection agent comprises: a primer or a probe.

### Claim 22 (depends on 14)

An agent or a combination of agents, wherein, the agent or the combination of agents specifically detect the modification on CPG site(s) of a target sequence, which is the full length or fragment of the polynucleotides of SEQ ID NO: 1, 3, 5 or 7 or the fragments thereof, or the polynucleotide of claim 14, and has at least one modified CpG site; the detection agent comprises: a primer, a probe.

### Claim 23 (depends on 22)

The agent or combination of agents according to claim 22, wherein, the polynucleotide is of the nucleotide sequence as shown in SEQ ID NO: 1, and the target sequence comprises the nucleotide fragment of residues 240-296 of SEQ ID NO: 1, the primer is as shown in SEQ ID NO: 9-12.

### Claim 24 (depends on 22)

The agent or combination of agents according to claim 22, wherein, the polynucleotide is of the nucleotide sequence as shown in SEQ ID NO: 3, and the target sequence comprises the nucleotide fragment of residues 279-323 of SEQ ID NO:3; he primer is as shown in SEQ ID NO: 12-15.

### Claim 25 (depends on 22)

The agent or combination of agents according to claim 22, wherein, the polynucleotide is of the nucleotide sequence as shown in SEQ ID NO: 5, and the target sequence comprises the nucleotide fragment of residues 186-235 of SEQ ID NO:5; the primer is as shown in SEQ ID NO: 12, 16-18.

### Claim 26 (depends on 22)

The agent or combination of agents according to claim 22, wherein, the polynucleotide is of the nucleotide sequence as shown in SEQ ID NO: 7, and the target sequence comprises the nucleotide fragment of residues 164-198 of SEQ ID NO:7; the primer is as shown in SEQ ID NO: 12, 19-21.

### Claim 27 (depends on 22)

A detection kit, comprising:
container(s) and the agent or combination of agents according to claim 22 in the container(s).

### Claim 28 (depends on 1)

A method of detecting the methylation profile of the polynucleotide of SEQ ID NO: 1, 3, 5 or 7 or the fragments thereof, or the polynucleotide of claim 1, a fragment thereof in a sample in vitro, comprising:
(i) providing the sample and extracting DNA;
(ii) treating the sample to be detected to convert the unmodified cytosine into uracil; the modification includes 5-methylation, 5-hydroxymethylation, 5-formylcytosine (5fC) or 5-carboxylcytosine (5-caC);
(iii) analyzing the modification of the polynucleotide or a fragment thereof in the genomic DNA treated by step (ii).

### Claim 29 (depends on 28)

The method according to claim 28, wherein, in step (iii), the analysis methods include: pyrosequencing, bisulfite conversion sequencing, qPCR, second generation sequencing, whole genome methylation sequencing, DNA enrichment detection, simplified bisulfite sequencing technology, HPLC, or their combination.

### Claim 30 (depends on 28)

The method according to claim 28, wherein, in step (ii), treating the DNA of step (i) with bisulfite.
